Evidence map›Paper›PMID 32923143›Full record

SynthesisOncoimmunology2020

A meta-analysis comparing responses of Asian versus non-Asian cancer patients to PD-1 and PD-L1 inhibitor-based therapy.

Ling Peng, Bao-Dong Qin, Kui Xiao, Song Xu, Jin-Song Yang, Yuan-Sheng Zang, Justin Stebbing, Li-Ping Xie

Open access · goldAbstract readMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Oncoimmunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 10 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed, 10 pooled it
2.9field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

48 citing papers in PubMed, 10 syntheses or guidelines pooled it, 78 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 2 countries.

Ling PengDepartment of Radiotherapy, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.ORCID 0000-0002-1359-4982
Bao-Dong QinDepartment of Medical Oncology, Changzheng Hospital, Second Military Medical Hospital, Shanghai, China.
Kui XiaoDepartment of Pulmonary and Critical Care Medicine, The Second Xiangya Hospital, Central South University, Changsha, China.
Song XuDepartment of Lung Cancer Surgery, Lung Cancer Institute, Tianjin Medical University General Hospital, Tianjin, China.
Jin-Song YangDepartment of Radiotherapy, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Yuan-Sheng ZangDepartment of Medical Oncology, Changzheng Hospital, Second Military Medical Hospital, Shanghai, China.
Justin StebbingDivision of Cancer, Department of Surgery and Cancer, Imperial College London, London, UK.ORCID 0000-0002-1117-6947
Li-Ping XieDepartment of Urology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
First Affiliated Hospital Zhejiang University · CNSecond Military Medical University · CNCentral South University · CNImperial College London · GBTianjin Medical University General Hospital · CN

Funding

Department of Health NIHR-RP-011-053
6 · The paper itself

Abstract

Background: Subgroup analysis of clinical trials of PD-1/PD-L1 inhibitors have reported ethnic differences in outcomes. We systematically collected published data and performed a meta-analysis to compare therapeutic efficacy in Asian and non-Asian patients receiving PD-1/PD-L1 inhibitors. Methods: Eligible studies included phase II and III prospective clinical trials with available subgroup data on Asian versus non-Asian populations. Overall survival (OS) and progression-free survival (PFS) were used to evaluate differences in outcome between Asian versus non-Asian cancer patients. Results: A total of 11,020 cancer patients from 19 prospective randomized controlled clinical trials were included. The overall estimated HR for OS was 0.69 with 95% CI of 0.61-0.77 in Asian versus 0.82 with 95% CI of 0.77-0.88 in non-Asian patients. The estimated hazard ratio (HR) for PFS measured 0.54 (95% CI, 0.32-0.76) and 0.69 (95% CI, 0.54-0.85) in Asian and non-Asian patients, respectively. Pooled ratios of OS HRs and PFS HRs reported in Asian versus non-Asian cancer patients were 0.84 (95% CI, 0.75-0.94) and 0.78 (95% CI, 0.59-0.97), respectively. Conclusions: This meta-analysis shows for the first time that Asian cancer patients have a significantly improved survival benefit than non-Asian patients receiving PD-1/PD-L1 inhibitor-based therapy.

Indexed as

NeoplasmsProgrammed Cell Death 1 ReceptorB7-H1 AntigenHumansImmune Checkpoint InhibitorsProspective StudiesB7-H1 AntigenImmune Checkpoint InhibitorsProgrammed Cell Death 1 ReceptorcancerEthnicimmune checkpoint inhibitormeta-analysis

Identifiers

PMID32923143
PMCPMC7458616
OpenAlexW3037990514

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.